• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Vaxcyte Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/7/25 4:03:56 PM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PCVX alert in real time by email
    pcvx-20250507
    0001649094FALSE00016490942025-05-072025-05-07

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
    _____________________________________________
    FORM 8-K
    _____________________________________________
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): May 7, 2025
    _____________________________________________
    Vaxcyte, Inc.
    (Exact name of Registrant as Specified in Its Charter)
    _____________________________________________
    Delaware01-3932346-4233385
    (State or Other Jurisdiction
    of Incorporation)
    (Commission File Number)(IRS Employer
    Identification No.)
    825 Industrial Road
    Suite 300
    San Carlos , California
     94070
    (Address of Principal Executive Offices)(Zip Code)
    Registrant’s Telephone Number, Including Area Code: (650) 837-0111
    Not Applicable
    (Former Name or Former Address, if Changed Since Last Report)
    _____________________________________________
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    o
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    o
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    o
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    o
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each class
    Trading
    Symbol(s)
    Name of each exchange on which registered
    Common Stock, $0.001 par value per sharePCVXThe Nasdaq Stock Market LLC
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
    Emerging growth company o
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o



    Item 2.02 Results of Operations and Financial Condition.
    On May 7, 2025, Vaxcyte, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2025. The full text of the press release is furnished as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference.
    The information in this Item 2.02 and Item 9.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
    Item 9.01 Financial Statements and Exhibits.
    (d)Exhibits
    Exhibit
    Number
    Description
    99.1
    Press Release of Vaxcyte, Inc., dated May 7, 2025
    104Cover Page Interactive Data File (embedded within the Inline XBRL document)



    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
    VAXCYTE, INC.
    Date:May 7, 2025By: /s/ Andrew Guggenhime
    Andrew Guggenhime
    President and Chief Financial Officer

    Get the next $PCVX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PCVX

    DatePrice TargetRatingAnalyst
    9/12/2025$38.00Neutral
    Goldman
    4/22/2025Overweight
    Cantor Fitzgerald
    12/20/2024$135.00Buy
    Goldman
    12/7/2023$69.00Buy
    Mizuho
    4/18/2023Outperform
    TD Cowen
    1/3/2023$52.00 → $58.00Buy
    Needham
    12/15/2022$66.00Buy
    Guggenheim
    11/17/2022$69.00Buy
    BTIG Research
    More analyst ratings

    $PCVX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, FINANCE Cowan Elvia covered exercise/tax liability with 482 shares, decreasing direct ownership by 2% to 26,156 units (SEC Form 4)

    4 - Vaxcyte, Inc. (0001649094) (Issuer)

    9/10/25 4:28:24 PM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Technical Ops Officer Dhaliwal Harpreet S. covered exercise/tax liability with 1,204 shares, decreasing direct ownership by 3% to 33,670 units (SEC Form 4)

    4 - Vaxcyte, Inc. (0001649094) (Issuer)

    9/10/25 4:28:01 PM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF OPERATING OFFICER Wassil Jim covered exercise/tax liability with 2,759 shares, decreasing direct ownership by 2% to 141,848 units (SEC Form 4)

    4 - Vaxcyte, Inc. (0001649094) (Issuer)

    9/10/25 4:27:29 PM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCVX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services

    New Agreement with Thermo Fisher Scientific Expands Domestic Capacity to Support Future Commercial Manufacturing of Vaxcyte's Broad-Spectrum Pneumococcal Conjugate Vaccine Candidates SAN CARLOS, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company, today announced a new agreement with Thermo Fisher Scientific Inc., the world leader in serving science, to bring additional fill-finish commercial manufacturing for Vaxcyte's broad-spectrum pneumococcal conjugate vaccines (PCVs) to the United States. As a key element of Vaxcyte's long-term U.S. commercial supply strategy, Thermo Fisher will provide custom commercial fill-finish ca

    9/30/25 8:30:00 AM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tentarix Biotherapeutics Strengthens Executive Team

    Tentarix Biotherapeutics LP, a biotechnology company developing best-in-class, targeted and conditionally active multispecific biologics, today announced four key executive changes that further strengthen its executive team and capabilities as it advances a differentiated pipeline into development. Ash Khanna, Ph.D., joins as Chief Business Officer; Dallas Jones, Ph.D., as Senior Vice President, Biology; and Tim Noffke as Vice President, Program Management and Chief of Staff. The Company also announced the promotion of Ankita Srivastava, Ph.D., to Senior Vice President, Biotherapeutics. "We are thrilled to welcome Ash, Dallas, and Tim to the team and to recognize Ankita's outstanding cont

    9/30/25 8:05:00 AM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose

    VAX-31 Optimized Dose, with Majority of Serotypes Dosed at 4.4mcg and Balance at 3.3mcg, is Designed to Elicit Even Stronger Immune Responses in Infant Population to Protect Against Invasive Pneumococcal Disease (IPD) Company Intends to Release Topline Data from Primary Immunization Series and Booster Dose Either Sequentially or Together by End of First Half of 2027 VAX-31 is Designed to Provide Greater Coverage Against Both Currently Circulating and Historically Prevalent Strains Relative to Standard-Of-Care Pneumococcal Conjugate Vaccines (PCVs) VAX-31 Offers Potential to Become the Most Broad-Spectrum PCV Covering ~92% of IPD and ~93% of Acute Otitis Media in U.S. Children Under Five

    9/3/25 7:30:00 AM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCVX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman initiated coverage on Vaxcyte with a new price target

    Goldman initiated coverage of Vaxcyte with a rating of Neutral and set a new price target of $38.00

    9/12/25 7:53:21 AM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Vaxcyte

    Cantor Fitzgerald initiated coverage of Vaxcyte with a rating of Overweight

    4/22/25 7:35:12 AM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on Vaxcyte with a new price target

    Goldman initiated coverage of Vaxcyte with a rating of Buy and set a new price target of $135.00

    12/20/24 7:47:04 AM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCVX
    SEC Filings

    View All

    Vaxcyte Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - Vaxcyte, Inc. (0001649094) (Filer)

    9/30/25 9:06:36 AM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Vaxcyte Inc.

    SCHEDULE 13G/A - Vaxcyte, Inc. (0001649094) (Subject)

    9/8/25 11:46:16 AM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Vaxcyte Inc.

    SCHEDULE 13G/A - Vaxcyte, Inc. (0001649094) (Subject)

    8/14/25 11:00:55 AM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCVX
    Leadership Updates

    Live Leadership Updates

    View All

    Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors

    SAN CARLOS, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed Dr. Olivier Brandicourt, a veteran biopharmaceutical industry executive and the former Chief Executive Officer of Sanofi S.A., to its Board of Directors. "We are thrilled to welcome Olivier to Vaxcyte's Board of Directors," said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. "He brings a wealth of biopharmaceutical expertise, with significant experience in commercial strategy and execution within the global vaccine market.

    5/1/25 8:00:29 AM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vaxcyte Appoints John Furey to Board of Directors

    SAN CARLOS, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed John Furey, a seasoned industry expert, to its Board of Directors. "We are thrilled to welcome John to Vaxcyte's Board of Directors and look forward to benefiting from his wealth of biopharmaceutical and vaccine expertise, including the manufacture, supply and commercialization of pneumococcal conjugate vaccines (PCVs)," said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. "As we continue to progress our PCV candidates, VAX-24

    7/2/24 8:30:00 AM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vaxcyte Appoints Whitney Jones as Chief People Officer

    -- Ms. Jones Joins Vaxcyte With Over 20 Years of Experience Leading People and Culture Strategies Across Multiple Industries -- SAN CARLOS, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the appointment of Whitney Jones as Chief People Officer. Ms. Jones will lead Vaxcyte's human resources strategy and operations, including people and culture, talent acquisition and management, learning and development, total rewards and employee engagement. "At Vaxcyte, we are proud to cultivate a culture that values coll

    1/16/24 4:01:00 PM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCVX
    Financials

    Live finance-specific insights

    View All

    Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study

    -- At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) -- -- At All Doses Evaluated, VAX-24 Elicited Substantial Immune Responses Following Primary Three-Dose Immunization Series; Topline Results Also Include Interim Booster Dose IgG Data Showing Robust Memory Responses Across All Doses -- -- Dose-Dependent Immune Responses Consistently Demonstrated and Little to No Evidence of Carrier Suppression Was Observed, Supporting Platform's Potential to Deliver Broadest-Spectrum Infant Pneumococcal Conjugate Vaccine (PCV) Candidates -- -- Company Selects VAX-24 Mid Dose (2.2mcg) as Basis for Optimized Dose Formu

    3/31/25 7:00:00 AM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study

    SAN CARLOS, Calif., March 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tomorrow, March 31, 2025, at 8:00 a.m. Eastern Time to present topline results from the VAX-24 infant Phase 2 study. This study is evaluating the safety, tolerability and immunogenicity of VAX-24, the Company's 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), compared to Prevnar 20® in healthy infants. To participate in the conference call, p

    3/30/25 5:00:00 PM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

    SAN CARLOS, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that it will report financial results for the fourth quarter and full year 2024 after market close on February 25, 2025. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a business update. To participate in the conference call, please dial 800-225-9448 (domestic) or 203-518-9708 (international) and refer to conference ID PCVXQ424. A live webcast

    2/12/25 4:05:00 PM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCVX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Vaxcyte Inc.

    SC 13G/A - Vaxcyte, Inc. (0001649094) (Subject)

    11/14/24 5:46:11 PM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vaxcyte Inc.

    SC 13G/A - Vaxcyte, Inc. (0001649094) (Subject)

    11/14/24 2:53:06 PM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vaxcyte Inc.

    SC 13G/A - Vaxcyte, Inc. (0001649094) (Subject)

    11/12/24 10:34:18 AM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care